TrialCompass TCL
Back to results
Phase 2RecruitingPriority 3 · Moderate priorityNCT05477264

Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is evaluating Tislelizumab as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 19 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Tislelizumab (DRUG): Induction therapy: Tislelizumab combined with radiation * Tislelizumab: 200mg, IV at 3-week intervals combined with radiotherapy. * Radiotherapy: 400Gy/20 fractions Maintenance therapy(after termination of combination therapy) * Tislelizumab: 200mg IV at 3-week intervals for up to 2 years until disease progression or intolerance.

Drugs / treatments
Tislelizumab
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type

NCT05477264

Phase: Phase 2 | Status: Recruiting | Priority: Medium

Plain-language summary

This Phase 2 trial is evaluating Tislelizumab as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 19 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

What's being tested

Tislelizumab (DRUG): Induction therapy: Tislelizumab combined with radiation * Tislelizumab: 200mg, IV at 3-week intervals combined with radiotherapy. * Radiotherapy: 400Gy/20 fractions Maintenance therapy(after termination of combination therapy) * Tislelizumab: 200mg IV at 3-week intervals for up to 2 years until disease progression or intolerance.

Drugs / treatments: Tislelizumab

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 38 patients

Primary endpoint: Complete response rate; Overall response rate

Ages: 19 Years to —

Start date: 2023-03-02 | Est. completion: 2026-12-31

Locations

0 US sites · 1 total

Contact

—

Sponsor: Won Seog Kim (OTHER)

Tags

ENKTL · Newly diagnosed · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT05477264

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.